Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Long-Term Investments: 2021-2024

Historic Long-Term Investments for Tg Therapeutics (TGTX) over the last 3 years, with Dec 2024 value amounting to $808,000.

  • Tg Therapeutics' Long-Term Investments rose 4233.96% to $48.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.8 million, marking a year-over-year increase of 4233.96%. This contributed to the annual value of $808,000 for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Tg Therapeutics' Long-Term Investments is $808,000, which was down 93.49% from $12.4 million recorded in FY2022.
  • In the past 5 years, Tg Therapeutics' Long-Term Investments ranged from a high of $35.5 million in FY2021 and a low of $808,000 during FY2024.
  • Moreover, its 2-year median value for Long-Term Investments was $6.6 million (2022), whereas its average is $6.6 million.
  • Data for Tg Therapeutics' Long-Term Investments shows a maximum YoY plummeted of 65.09% (in 2022) over the last 5 years.
  • Yearly analysis of 3 years shows Tg Therapeutics' Long-Term Investments stood at $35.5 million in 2021, then slumped by 65.09% to $12.4 million in 2022, then reached $808,000 in 2024.